Epilepsy Market in the US 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
05.1 Epilepsy
05.1.1 Etiology
05.1.2 Signs and Symptoms
05.1.3 Diagnosis
05.1.4 Epidemiology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Generation of Drugs
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2014
16.2.1 GlaxoSmithKline
16.2.2 UCB
16.2.3 Pfizer
16.3 Other Prominent Vendors
17. Key Vendor Analysis
17.1 GlaxoSmithKline
17.1.1 Key Facts
17.1.2 Business Overview
17.1.3 Business Segmentation
17.1.4 Business Segmentation by Revenue 2012 and 2013
17.1.5 Sales by Geography
17.1.6 Pipeline Products
17.1.7 Business Strategy
17.1.8 Key Information
17.1.9 SWOT Analysis
17.2 Pfizer
17.2.1 Key Facts
17.2.2 Business Overview
17.2.3 Business Segmentation by Revenue 2013
17.2.4 Business Segmentation by Revenue 2012 and 2013
17.2.5 Geographical Segmentation by Revenue
17.2.6 Business Strategy
17.2.7 Key Developments
17.2.8 SWOT Analysis
17.3 UCB
17.3.1 Key Facts
17.3.2 Business Overview
17.3.3 Product Segmentation by Revenue 2013
17.3.4 Product Segmentation by Revenue 2012 and 2013
17.3.5 Geographical Segmentation by Revenue 2013
17.3.6 Business Strategy
17.3.7 Recent Developments
17.3.8 SWOT Analysis
18. Other Reports in this Series